What Happened?

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales. 

While the sector is traditionally defensive, the hot PPI print creates a two-pronged headwind. First, rising service-sector inflation (up 1.2% monthly) increases the operating costs for hospital systems and providers. Second, as inflation becomes a dominant political issue, drug companies' visible price-setting power makes them a primary target for regulatory intervention.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Testing & Diagnostics Services company NeoGenomics (NASDAQ: NEO) fell 4.5%. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
• Drug Development Inputs & Services company Charles River Laboratories (NYSE: CRL) fell 4.5%. Is now the time to buy Charles River Laboratories? Access our full analysis report here, it’s free.

Zooming In On Charles River Laboratories (CRL)

Charles River Laboratories’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 26 days ago when the stock gained 3.7% on the news that the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs. 

For healthcare providers and medical device manufacturers, lower oil prices directly reduce the cost of operating large hospital facilities and shipping sensitive medical equipment. This margin relief is vital for a sector that has been squeezed by high transportation overhead, allowing for a more favorable outlook on quarterly earnings. 

The "risk-on" sentiment sparked by the ceasefire also drove capital back into high-growth biotech and pharmaceutical names. As broader market volatility recedes, investors are more willing to fund long-term R&D and clinical trials that were previously shadowed by macroeconomic uncertainty. The stabilization of the global economy ensures that both elective procedures and pharmaceutical demand remain on a steady upward trajectory for the remainder of 2026.

Charles River Laboratories is down 20.3% since the beginning of the year, and at $161.39 per share, it is trading 28.8% below its 52-week high of $226.77 from January 2026. Investors who bought $1,000 worth of Charles River Laboratories’s shares 5 years ago would now be looking at only $502.77.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.